2024-03-28T08:59:20Z
https://nagoya.repo.nii.ac.jp/oai
oai:nagoya.repo.nii.ac.jp:02004209
2023-04-28T06:33:50Z
499:508:509:1669094631719
The effects of ustekinumab on small intestinal lesions and stenotic lesions
Wada, Hirotaka
Murate, Kentaro
Nakamura, Masanao
Furukawa, Kazuhiro
Kakushima, Naomi
Yamamura, Takeshi
Maeda, Keiko
Sawada, Tsunaki
Ishikawa, Eri
Ishikawa, Takuya
Ohno, Eizaburo
Honda, Takashi
Kawashima, Hiroki
Nakayama, Goro
Hattori, Norifumi
Umeda, Shinichi
Ishigami, Masatoshi
open access
Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International
Crohn’s disease
small bowel endoscopy
stenotic small intestine lesion
total colonoscopy
ustekinumab
Crohn’s disease patients suffer from symptoms originating from small bowel lesions, including strictures. As many of these patients also have a potential risk of surgery, it is important to consider various therapeutic strategies for small bowel lesions. We retrospectively analyzed the therapeutic effects of ustekinumab, interleukin-12 and -23 blocker, for small intestinal lesions and intestinal stenosis in order to contribute to the optimal management of Crohn’s disease. Patients who underwent total colonoscopy or small bowel endoscopy before and after the introduction of ustekinumab were enrolled in this study. The colonoscopy findings were evaluated by the simple endoscopic score for Crohn’s disease, and small bowel endoscopy findings were evaluated using the modified simple endoscopic score for Crohn’s disease. Endoscopic scores were compared before and after the introduction of ustekinumab and between the responders and non-responders to ustekinumab. Responders were defined as those whose Crohn’s disease activity index score at 24 weeks fell below 150 points, or those whose score decreased by more than 100 points from the pre-induction level. A total of 50 patients were enrolled in the study, and the number of responders was 35. Pre-induction simple endoscopic scores were lower for responders, but no significant difference was observed in the modified simple endoscopic scores. The total decrease in the endoscopic score was significantly higher in the responders for both the small and large intestine. Use of ustekinumab as a first-line treatment for patients with small bowel lesions or stricture-prone lesions may be a new treatment consideration in the future.
Nagoya University Graduate School of Medicine, School of Medicine
2022-11
eng
departmental bulletin paper
VoR
https://doi.org/10.18999/nagjms.84.4.825
http://hdl.handle.net/2237/0002004209
https://nagoya.repo.nii.ac.jp/records/2004209
10.18999/nagjms.84.4.825
https://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/844.html
0027-7622
2186-3326
Nagoya Journal of Medical Science
84
4
825
838
https://nagoya.repo.nii.ac.jp/record/2004209/files/13_Wada.pdf
application/pdf
3.2 MB
2022-11-24